A Phase 3 interventional study of Certolizumab pegol (CDP870) in Rheumatoid Arthritis, sponsored by UCB Pharma. Completed at 79 sites in 13 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-12-01.
Sponsored by UCB Pharma · Phase 3, Interventional, and Treatment
Patients will be assigned to one of three treatment groups. Study medication is administered over a 52 week study duration.
3,554 studies on the registry are indexed under Arthritis; 317 are open to participants now.
This study's enrollment of 950 is above the median of 90 across 2,377 interventional studies indexed under Arthritis.
Browse Arthritis studies →UCB Pharma is the lead sponsor of 238 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Active RA disease at Screening and Baseline as defined by:
Exclusion Criteria:
To assess the efficacy of CDP870 in combination with Methotrexate in the treatment of Rheumatoid Arthritis and prevention of structural damage by measuring the ACR20 response at week 24 and change from Baseline
Change from Baseline in mTSS at week 24, Change from Baseline in HAQ-DI at weeks 24 and 52, ACR20 responder rate at week 52, ACR50 and ACR70 responder rate at weeks 24 and 52
This study is completed, as verified in Nov 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
UCB Pharma